|Bid||8.05 x 800|
|Ask||9.90 x 1200|
|Day's Range||9.25 - 10.34|
|52 Week Range||4.60 - 50.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.00|
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
By John Vandermosten, CFA NASDAQ:ACHV On Monday, Achieve Life Sciences, Inc. (NASDAQ:ACHV) updated the investment community on the status of New Zealand’s RAUORA 1 study, which was expected to announce completion in the months leading up to the September SRNT conference. While full results were not provided, the study’s principal investigator did announce that cytisinicline was as good as
SEATTLE and VANCOUVER, BC , June 29, 2020 /CNW/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41 per share in a registered direct offering, resulting in total gross proceeds of approximately $6 million , prior to deducting placement agent fees and estimated offering expenses. Lake Street Capital Markets LLC is acting as exclusive placement agent for the registered direct offering. The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-229019), which was declared effective by the United States Securities and Exchange Commission ("SEC") on February 11, 2019 .